Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women

Journal of the Operational Research Society

Volumn 56, Issue 2, 2005, Pages 214-221

  Stevenson, M D ^a   Brazier, J E ^a   Calvert, N W ^a   Lloyd Jones, M ^a   Oakley, J E ^b   Kanis, J A ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cost benefit; Decision analysis; Health service; Simulation

Indexed keywords

COMPUTER SIMULATION; COST EFFECTIVENESS; DECISION THEORY; FRACTURE; HEALTH CARE; MATHEMATICAL MODELS; PATIENT TREATMENT;

COST BENEFITS; HEALTH SERVICES; OPTIMAL HEALTH; OSTEOPOROSIS;

DISEASE CONTROL;

EID: 13444254466     PISSN: 01605682     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jors.2601903     Document Type: Article

References (29)

1. Consensus development conference (1991). Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 90: 107-110.
2. Kanis JA et al (2000). An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporosis International 11: 192-202.
3. Department of Health and the Association of the British Pharmaceutical Industry (1994). Guidelines for the Economic Evaluation of Pharmaceuticals (Press release). Department of Health: London.
4. Dolan P and Torgerson DJ (1998). The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporosis Int 8: 611-617.
5. NICE FAD Reference National Institute for Clinical Excellence (2004). Appraisal Consultation Document: The Clinical Effectiveness and Cost Effectiveness of Technologies for the Secondary Prevention of Osteoporotic Fractures in Postmenopausal Women. National Institute for Clinical Excellence: London, Available from: www.nice.org.uk.
6. Drummond MF et al (1997). Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford Medical Publications: Oxford.
7. Weinstein MC and Statson WB (1977). Foundations of cost-effectiveness analysis for health and medical practices. N Eng J Med 296: 716.
8. Birch S and Gafni A (1992). Cost-effectiveness/utility analyses: do current decision rules lead us where we want to be? J Health Econ 11. 279-296.
9. Raftery J (2001). NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323: 1300-1303.
10. Briggs AH and Gray AM (1999). Handling uncertainty when performing economic evaluations of healthcare interventions. Health Technol Assess 3(2).
11. Fenwick E et al (2001). Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 10: 779-787.
12. Eastman RC et al (1997). Model of complications of NIDDM. Model construction and assumptions. Diabe Care 20: 725-727.
13. Department of Health (1995). Policy Appraisal and Health. Department of Health: London.
14. Government Actuary Department (1999). Expectation of life United Kingdom females. http://www.gad.gov.uk/Life_Tables/ docs/whltukf.xls
15. Stevenson MD et al (2004). A systematic review and economic evaluation of interventions for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assessment, in press.
16. Netten A et al (1998). Unit costs of health and social care. Canterbury PSSRU, University of Kent: Canterbury, UK.
17. HM Treasury. GDP and GDP Deflators at Market Prices, 2000. http://www.hm-treasury.gov.uk/economic_data_and_tools/gdp_ deflators/data-gdp-fig.cfm
18. Murray C et al (2002). Utility following a fracture in a group of elderly women. Qual Life Res 11: 642.
19. National Osteoporosis Foundation (1998). Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Introduction. Osteoporosis Int 8: S7-S80.
20. Oleksik A et al (2000). Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15: 1384-1392.
21. Dolan P et al (1999). Health-related quality of life of Colles' fracture patients. Osteoporosis Int 9: 196-199.
22. Kanis JA et al (2004). The risk and burden of vertebral fractures in Sweden. Osteoporosis Int 15: 20-26.
23. Hutton J et al (1996). A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9(Suppl 2): 8-22.
24. Kanis JA et al (2002). Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6(29).
25. Stinnett AA and Paltiel AD (1997). Estimating CE ratios under second-order uncertainty. Med Decision Making 17: 483-489.
26. Stevenson MD et al (2004). Gaussian Process modelling in conjunction with individual patient simulation modelling. A case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis. Med Decision Making 24: 89-100.
27. Briggs A (2000). Uncertainty in cost-effectiveness models. Pharmacoeconomics 17: 479-500.
28. Klotzbeucher CM et al (2000). Patients with prior fracture have a increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15: 721-727.
29. Todd CJ et al (1999). Anglian Audit of Hip Fracture 2. Cambridge Health Services Research Group, University of Cambridge: Cambridge.